Type 2 diabetes classification: a data-driven cluster study of the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort

Diana Hedevang Christensen, Sia K Nicolaisen, Emma Ahlqvist, Jacob V Stidsen, Jens Steen Nielsen, Kurt Hojlund, Michael H Olsen, Sonia Garcia-Calzón, Charlotte Ling, Jørgen Rungeby, Ivan Brandslund, Peter Vestergaard, Niels Jessen, Torben Hansen, Charlotte Brons, Henning Beck-Nielsen, Henrik T Sorensen, Reimar W Thomsen, Allan Vaag

ABSTRACT

Introduction A Swedish data-driven cluster study identified four distinct type 2 diabetes (T2D) clusters, based on age at diagnosis, body mass index (BMI), hemoglobin A1c (HbA1c) level, and homeostatic model assessment 2 (HOMA2) estimates of insulin resistance and beta-cell function. A Danish study proposed three T2D phenotypes (insulinopenic, hyperinsulinemic, and classical) based on HOMA2 measures only. We examined these two new T2D classifications using the Danish Centre for Strategic Research in Type 2 Diabetes cohort.

Research design and methods In 3529 individuals, we first performed a k-means cluster analysis with a forced k-value of four to replicate the Swedish clusters: severe insulin deficient (SIDD), severe insulin resistant (SIRD), mild age-related (MARD), and mild obesity-related (MOD) diabetes. Next, we did an analysis open to alternative k-values (ie, data determined the optimal number of clusters). Finally, we compared the data-driven clusters with the three Danish phenotypes.

Results Compared with the Swedish findings, the replicated Danish SIDD cluster included patients with lower mean HbA1c (86 mmol/mol vs 101 mmol/mol), and the Danish MOD cluster patients were less obese (mean BMI 32 kg/m² vs 36 kg/m²). Our data-driven alternative k-value analysis suggested the optimal number of T2D clusters in our data to be three, rather than four. When comparing the four replicated Swedish clusters with the three proposed Danish phenotypes, 81%, 79%, and 69% of the SIDD, MOD, and MARD patients, respectively, fitted the classical T2D phenotype, whereas 70% of SIRD patients fitted the hyperinsulinemic phenotype. Among the three alternative data-driven clusters, 60% of patients in the most insulin-resistant cluster constituted 76% of patients with a hyperinsulinemic phenotype.

Conclusion Different HOMA2-based approaches did not classify patients with T2D in a consistent manner. The T2D classes characterized by high insulin resistance/hyperinsulinemia appeared most distinct.

INTRODUCTION

Type 2 diabetes (T2D) is the most frequent type of diabetes (~95% of patients) and is a heterogeneous disease. A recent Swedish data-driven cluster analysis of individuals with newly diagnosed diabetes in the Swedish All New Diabetics in Scania (ANDIS) cohort suggested a classification encompassing four distinct T2D clusters. These were labelled severe insulin-deficient (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), and mild age-related diabetes (MARD). A fifth cluster was labeled

Significance of this study

What is already known about this subject?

► A Swedish cluster analysis has identified four distinct type 2 diabetes (T2D) clusters based on age at diagnosis, body mass index, HbA1c, and HOMA2 estimates of insulin resistance and beta-cell function.

► A Danish study has suggested three T2D phenotypes based only on HOMA2 measures: insulinopenic, hyperinsulinemic, and classical.

What are the new findings?

► Using an identical data-driven cluster analysis in the Danish Centre for Strategic Research in Type 2 Diabetes cohort (n=3529 patients) and forcing k=4 clusters, we could replicate the four Swedish T2D clusters.

► Nevertheless, an analysis open to alternative k-values suggested the existence of three rather than four clusters.

► Neither the four nor the three clusters overlapped substantially with the Danish phenotype classification. The diabetes classes characterized by high insulin resistance/hyperinsulinemia showed the largest overlap and appeared most distinct.

How might these results change the focus of research or clinical practice??

► Subclassification of patients with T2D at diagnosis may associate with individual prognosis and treatment. Our results suggest that there is a need to further refine T2D subclassifications.
severe autoimmune diabetes (SAID) and composed of individuals with presence of glutamic acid decarboxy-
lase antibodies (GADA) (ie, type 1 diabetes and latent autoimmune diabetes of adults). The four T2D clusters
were identified based on GADA negativity and a data-
driven de novo cluster analysis based on five variables:
age at diabetes diagnosis, body mass index (BMI), hemos-
globin A1c (HbA1c), and homeostatic model assessment
2 (HOMA2) estimates of insulin resistance (HOMA2-IR)
and beta-cell function (HOMA2-B).

Based solely on HOMA2-sensitivity (HOMA2-S) and
HOMA2-B measurements, a Danish study of recent-onset
T2D patients in the Danish Centre for Strategic Research
in Type 2 Diabetes (DD2) cohort proposed an easy-to-use
classification. The investigators proposed the existence
of three T2D phenotypes, labelled insulinopenic, clas-
sical, and hyperinsulinemic diabetes.

Features common to the two proposed T2D classifica-
tions were clusters and phenotypes characterized by
distinct and different clinical characteristics including
heritability and genetics, as well as differential risk of
diabetes complications. Thus, allocation of patients to
more refined T2D classes at time of diabetes diagnosis
may have the potential for more individualized diabetes
treatment in the future, as well as for individualized strat-
egies for prevention of complications.

In the current study, we investigated whether the four
identified Swedish data-driven T2D clusters could be
replicated in the Danish DD2 cohort. We also performed
a de novo data-driven analysis open to an alternative
number of clusters, and then compared the data-driven
clusters to the Danish phenotypes, with respect to distri-
butions and clinical characteristics including heritability
and complications.

**METHODS**

**Setting**

The DD2 project has enrolled newly or recently diag-
nosed T2D patients since November 2010. Enrollment
takes place in hospital specialist outpatient clinics or
general practitioners' offices (53% and 47%, respec-
tively) throughout Denmark. Denmark has a free tax
supported healthcare system. All individuals aged ≥18
years with new clinically diagnosed T2D in Denmark after
1 January 2009, with or without initiation of glucose-
lowering therapy, are eligible for inclusion in the DD2
cohort and biobank (online supplemental table S1). At
enrollment, interview and clinical examination data for
each patient are recorded, and blood and urine samples
are obtained. The unique civil personal registration
number assigned to all Danish citizens is used to link the
DD2 research database to nationwide Danish health regis-
tries. These include the Danish National Patient Registry,
which contains a complete hospital history including all
hospital-diagnosed diabetes complications; the Danish
National Health Service Prescription Database, which
contains information on filled prescriptions; and the
Danish Civil Registration System, which contains infor-
mation on vital status and migration. For a subcohort
of DD2 patients (~2/3 of the cohort), additional detailed
clinical data including HbA1c levels and BMI are linked
from the Danish Diabetes Database for Adults (online
supplemental figures S1 and S2).

Additional information on the DD2 project is available
in a publication and at www.dd2.nu.

**Study cohort**

The source population included the first 5987 consecu-
tively enrolled DD2 participants from November 2010 to
February 2015.

The study cohort was restricted to persons with at least
one measure of each of the variables used in the origi-
nal Swedish cluster analysis: age at diabetes diagnosis,
BMI, HbA1c, fasting serum C-peptide, and fasting plasma
glucose, as well as GADA. As in the Swedish study, we
excluded those with extreme outliers (ie, values more
than 5 SDs from the mean, n=78). We also excluded
patients with secondary diabetes (n=43), rare types of
diabetes (n=7), for example, Cushing’s disease (online
supplemental table S2), and glucocorticoid-associated
diabetes (n=109). In addition, we excluded GADA-
positive patients (n=60), defined as those with a GADA
titer ≥32 IU/mL.

**Biomarkers and cluster variables**

Testing of GADA, fasting serum C-peptide, and fasting
plasma glucose biomarkers was performed in the ISO
15189 accredited laboratory at University Hospital of
Southern Denmark, Vejle, using the blood samples
stored after DD2 enrollment (ie, median 1.5 years after
diabetes diagnosis date). The analysis methods have
been described in detail. We used the HOMA calcu-
lator (University of Oxford, Oxford, UK) to calculate
HOMA2 measures based on fasting serum C-peptide
and fasting plasma glucose concentrations. The diabetes
diagnosis date (index date) was defined as the date of
the first indication of diabetes from any available data
source including date of first prescription redemption of
a glucose-lowering drug (see online supplemental table
S2 for details). Age was calculated based on this date.
HbA1c and BMI values registered closest to this date were
applied in the analyses (online supplemental figure S2).

These variables were used to classify patients using the
k-means cluster method.

**T2D phenotypes**

In addition to the k-means cluster method, patients in
the DD2 cohort were classified according to HOMA2
measures into an insulinopenic phenotype (high insulin
sensitivity, low beta-cell function), a classic phenotype
(low insulin sensitivity, low beta-cell function), and a
hyperinsulinemic phenotype (low insulin sensitivity, high
beta-cell function), as previously described. High and
low insulin sensitivity and beta-cell function were defined
by the median HOMA2-S and HOMA2-B values in a
general population sample with normal glucose tolerance3 (online supplemental table S2).

A few individuals (n=15) had high insulin sensitivity and high beta-cell function. These were excluded in the previous DD2 phenotype study.1 In accordance with inclusion and exclusion criteria in the original Swedish cluster study, these 15 individuals were included in our cluster study.

Statistical analysis
De novo cluster analyses
All our data-driven cluster analyses were based on the same cluster variables included in the data-driven Swedish k-means cluster analysis: age, BMI, HbA1c, HOMA2-IR, and HOMA2-B. We also applied similar cluster rules.2

Thus, all values were centered to a mean value of 0 and an SD of 1. The cluster analyses were performed separately for males and females to account for any differences by biological sex, and the clusters then were combined. We used the kmeansruns function (runs=100) in the fpc package (V.2.2.8) in R to perform the de novo k-means clustering. We resampled the dataset 2000 times and computed Jaccard similarities to the original dataset in order to evaluate clusterwise stability.13

We performed the following de novo cluster analyses:

Replication of the Swedish T2D clusters, forced k-value=4
As one of our main aims was to replicate the Swedish T2D clusters in the Danish cohort, we did the cluster analysis forcing a k-value of four (ie, four clusters) as in the Swedish study. Cluster labels were assigned by comparing cluster variable means to those in the Swedish study.

New DD2 clusters, alternative k-value
To allow data to determine the number of clusters, rather than forcing a k-value of 4, we visually evaluated the optimal number of clusters. We selected the average silhouette method a priori because it was used in most previous diabetes cluster analyses2 14–16 and is considered the most objective method. We then reran the de novo k-means cluster analysis on the DD2 cohort using the alternative k-value. To test the robustness of the average silhouette method, we applied two commonly used alternative methods: the elbow method and the gap statistic method.

Additional analyses
We performed the following additional analyses:

1. Pretreatment HbA1c: we restricted the cohort to patients with available data on HbA1c prior to glucose-lowering drug initiation (if any), that is, pretreatment HbA1c. This was done to make the DD2 cohort more comparable with the Swedish ANDIS cohort, all of whose members had data on pretreatment HbA1c level. We used a k-value of 4.

2. DD2 enrolment date as index date: there may be a delay between the diabetes diagnosis date in clinical practice and enrolment/blood sampling for HOMA2 measurements in the DD2 cohort. We therefore performed a sensitivity analysis using the DD2 enrolment date as the index date, that is, the age at DD2 enrolment and the HbA1c and BMI values measured closest to DD2 enrolment. We used a k-value of 4.

3. Cluster assignment based on coordinates from the Swedish ANDIS cohort: in our main analysis, we assigned each DD2 patient to one of the four clusters based on centroids identified in the DD2 cohort (ie, de novo analysis). In addition, we replicated the four Swedish clusters by assigning each DD2 patient to the cluster in the Swedish ANDIS cohort to which each DD2 patient was most similar. All values were centered using the mean and SD observed in the ANDIS cohort, and patients were then assigned to a cluster using the centroid values from the ANDIS cohort.2

4. Omitting variables: we reran the main and the alternative k-value cluster analyses (de novo) while alternately omitting one variable in order to test cluster stability according to the used variables.

Characteristics of clusters
We provided characteristics for each of the four replicated Swedish clusters, for the three new alternative k-value DD2 clusters, and for the three DD2 phenotypes. If relevant, we included characteristics both as of the diabetes diagnosis date and as of the DD2 enrolment date (ie, date of HOMA2 measurement).

Patient flow across clusters
We used Sankey diagrams to compare patient flow across the clusters identified based on the different analyses, that is, from the four replicated Swedish clusters to the new alternative k-value DD2 clusters and from these two de novo cluster classifications to the T2D phenotypes. To allow comparisons with the phenotypes, we plotted HOMA2-B against HOMA2-S for each patient, marked the phenotype classification, and colored each patient by cluster allocation. Moreover, we compared the four replicated Swedish clusters identified using the de novo cluster method with those identified based on centroid/means from the ANDIS cohort.

All statistical analyses were conducted using SAS V.9.4 (SAS Institute Inc) and R V.4.0.3 (R Core Team, 2020).

RESULTS
In total, 3825 (64%) of the 5987 patients enrolled in DD2 during the study period had data on all key cluster variables. Of these, 3529 (59%) patients were eligible for further analyses (online supplemental figure S3) (2074 males, 1455 females).

De novo cluster analyses
Replication of the four data-driven Swedish T2D clusters
The distribution of patients in the four clusters was similar for females and males. Overall, 8% of patients were in the SIDD cluster, 23% in the SIRD cluster, 26% in the MOD cluster, and 42% in the large MARD cluster (figure 1, online supplemental figure S4). The distribution of
variables used for clustering showed a pattern similar to
that in the Swedish ANDIS cohort. However, the mean
HbA1c level was slightly lower in the SIDD cluster in
the DD2 cohort (86 mmol/mol) compared with the
SIDD cluster in the Swedish ANDIS cohort (101 mmol/
mol). Moreover, the cluster most similar to the Swedish
MOD cluster was characterized by less obesity and lower
beta-cell function in the DD2 cohort compared with the
ANDIS cohort (mean BMI: 32 kg/m² vs 36 kg/m²; mean
HOMA2-B: 81% vs 95%) (table 1, figure 1 and online
supplemental figure S4). Overall, variables largely over-
lapped across the four clusters.

Examination of patient characteristics showed that
patients allocated to the SIRD and MARD clusters had
the highest prevalence of macrovascular complications
(table 1). SIRD cluster patients had the highest prev-
ance of kidney disease, whereas the highest prevalence
of diabetic eye disease was observed in the MARD cluster.
Family history of diabetes was most common among
MOD cluster patients. The proportion of users of all
types of glucose-lowering drugs at DD2 enrollment date
was highest in the SIDD cluster.

New alternative k-value T2D clusters in the DD2 cohort
Visual evaluation (online supplemental figure S5)
suggested a varying number of clusters. However, we
considered a k-value of three, based on the average
silhouette method, to be the optimal number of clusters.
This yielded three clusters: New Cluster 1 included 433
patients (12%) and was characterized by insulin defi-
ciency, poor glycemic control, low insulin resistance, and
younger age (most similar to the SIDD cluster in ANDIS).
New Cluster 2 included 1131 patients (32%) and was
characterized by hyperinsulinemia, insulin resistance, and
a high BMI (most similar to the SIRD cluster in the
ANDIS cohort). New Cluster 3 included 1965 patients
(56%). This cluster was characterized by high age and
low insulin resistance (most similar to the MARD cluster
in ANDIS) (table 2, figure 1 and online supplemental
figure S6). Accordingly, the Sankey diagram (figure 2A)
illustrates that patients allocated to the SIDD, SIRD, and
MARD clusters, when forcing a k-value of four, primarily
were reallocated to New Clusters 1, 2 and 3, respect-
ively, when the cluster analysis was repeated with a k-value
of three. In contrast, patients originally allocated to the
MOD cluster were redistributed to all three New DD2 Clus-
ters, in particularly New Cluster 3, which also
encompassed patients from the original MARD cluster.

Table 2 shows that among the three New DD2 Clus-
ters, patients allocated to New cluster 2 (characterized by
hyperinsulinemia) had the highest prevalence of macro-
vascular complications and kidney disease, while those
in New Cluster 3 (characterized by high age) had the
highest prevalence of eye disease. Patients in New Cluster
1 (characterized by insulin deficiency) more often had
a family history of diabetes and most often were using
glucose-lowering drugs as of the DD2 enrollment date.

For both the analysis replicating the Swedish clusters
and the new alternative k-value DD2 cluster analysis, the
Jaccard means were above 0.75, regardless of sex, indi-
cating reasonably high cluster stability (online supple-
mental table S3).13

Comparison with the Danish T2D phenotypes

While comparing patient distribution across the four repli-
cated Swedish clusters and the three Danish T2D pheno-
types, 81% of the SIDD patients, 79% of the MOD patients,
and 69% of the MARD patients all exhibited the classical
phenotype. In comparison, 70% of the SIRD patients
exhibited the hyperinsulinemic phenotype (figures 2B and 3). For
the New alternative k-value DD2 Clusters, 60% of patients
in the hyperinsulinemic cluster (New Cluster 2) repre-
tended 76% of patients with a hyperinsulinemic phenotype
(figure 2C). In accordance, the highest prevalence of macro-
vascular complications and kidney disease were observed
Table 1  Patient characteristics: de novo replication of the four Swedish T2D clusters in the DD2 cohort

| Characteristic                                      | SIDD cluster | SIRD cluster | MOD cluster | MARD cluster | Total  |
|-----------------------------------------------------|--------------|--------------|-------------|--------------|--------|
| Male sex, n (%)                                     | 186 (64.5)   | 502 (60.5)   | 555 (60.0)  | 831 (55.9)   | 2074 (58.8) |
| Diabetes duration on DD2 enrollment date, years, median (quartiles) | 1.3 (0.4 ; 3.2) | 1.5 (0.5; 2.6) | 1.8 (0.5; 3.2) | 1.4 (0.5; 2.7) | 1.5 (0.5; 2.9) |
| Age on diabetes diagnosis date, years, mean (SD)*   | 53.6 (10.7)  | 59.2 (9.9)   | 48.6 (8.1)  | 66.9 (6.6)   | 59.2 (11.2) |
| Age on DD2 enrollment date, years, median (quartiles) | 56.3 (48.6; 63.4) | 62.3 (54.6; 67.9) | 52.0 (46.6; 56.8) | 68.2 (64.0; 73.2) | 62.6 (53.8; 68.9) |
| HOMA2-B, %, mean (SD)*†                             | 67.9 (32.2)  | 136.0 (37.4) | 81.0 (27.5) | 86.8 (26.3)  | 95.3 (37.9) |
| BMI, kg/m², mean (SD)*§                             | 31.9 (5.7)   | 36.4 (6.1)   | 31.5 (5.1)  | 27.9 (4.0)   | 31.1 (6.0)  |
| Waist circumference, cm, median (IQR), n=2526        | 110 (100; 118)| 118 (110; 126)| 105 (97; 114)| 99 (92; 107) | 106 (97; 116) |
| Alcohol, >14/21 units/week (M/F), n (%)             | 14 (4.9)     | 58 (7.0)     | 55 (5.9)    | 113 (7.6)    | 241 (6.8)  |
| Days per week with ≥30 min physical activity, n (%) | 0            | 44 (15.3)    | 195 (23.5)  | 139 (15.0)   | 155 (10.4) |
| 1–2                                                 | 74 (25.7)    | 199 (24.0)   | 197 (21.3)  | 242 (16.3)   | 712 (20.2) |
| ≥3                                                  | 170 (59.0)   | 435 (52.5)   | 589 (63.7)  | 1090 (73.3)  | 2284 (64.7) |
| Smoking, n=3225                                      |              |              |             |              |        |
| Current                                             | 56 (19.4)    | 152 (18.3)   | 200 (21.6)  | 215 (14.5)   | 623 (17.7) |
| Former                                              | 72 (25.0)    | 214 (25.8)   | 191 (20.7)  | 384 (25.8)   | 861 (24.4) |
| Never                                               | 136 (47.2)   | 390 (47.0)   | 453 (49.0)  | 762 (51.2)   | 1741 (49.3) |
| ≥1 relative with diabetes, n (%)                    | 156 (54.2)   | 404 (48.7)   | 557 (60.2)  | 763 (51.3)   | 1880 (53.3) |
| LDL cholesterol, median (quartiles), n=3412          | 2.6 (1.9; 3.3)| 2.3 (1.8; 2.9)| 2.3 (1.8; 3.0)| 2.2 (1.8; 2.9)| 2.3 (1.8; 3.0)|
| HDL cholesterol, median (quartiles), n=2085          | 1.0 (0.9; 1.2)| 1.1 (0.9; 1.3)| 1.1 (1.0; 1.4)| 1.4 (1.1; 1.6)| 1.2 (1.0; 1.4)|
| Triglyceride, median (quartiles), n=3343             | 2.2 (1.6; 3.2)| 1.9 (1.4; 2.8)| 1.7 (1.2; 2.6)| 1.4 (1.0; 1.9)| 1.6 (1.2; 2.4)|
| Systolic blood pressure, median (quartiles), n=3386  | 135 (126; 143)| 131 (125; 140)| 130 (121; 140)| 131 (125; 140)| 130 (124; 140)|
| Diastolic blood pressure, median (quartiles), n=3386 | 83 (80; 90)  | 80 (75; 88)  | 82 (77; 89) | 80 (71; 84) | 80 (75; 86) |
| Macrovascular complications, n (%)                  |              |              |             |              |        |
| Any CVD (on diagnosis date)                         | 37 (12.9)    | 218 (26.3)   | 98 (10.6)   | 353 (23.7)   | 706 (20.9) |
| Any CVD (on DD2 enrollment date)                    | 61 (21.2)    | 266 (32.1)   | 139 (15.0)  | 413 (27.8)   | 879 (24.9) |
| Microvascular complications, n (%)                 |              |              |             |              |        |
| Diabetes+eye disease (on diagnosis date)           | 9 (3.1)      | 46 (5.6)     | 18 (2.0)    | 102 (6.9)    | 175 (5.0) |
| Diabetes+eye disease (on DD2 enrollment date)      | 28 (9.7)     | 67 (8.1)     | 44 (4.8)    | 162 (10.9)   | 301 (8.5) |
| Diabetes+neuropathy (on diagnosis date)            | 18 (6.3)     | 58 (7.0)     | 52 (5.7)    | 87 (5.9)     | 215 (6.1) |
|                                      | SIDD cluster | SIRD cluster | MOD cluster | MARD cluster | Total  |
|--------------------------------------|--------------|--------------|-------------|--------------|--------|
| Diabetes+neuropathy (on DD2 enrollment date) | 28 (9.7)     | 79 (9.5)     | 75 (8.1)    | 114 (7.7)    | 296 (8.4) |
| Diabetes-renal disease (on diagnosis date)   | 2 (0.7)      | 13 (1.6)     | 5 (0.5)     | 7 (0.5)      | 27 (0.8)  |
| Diabetes-renal disease (on DD2 enrollment date) | 3 (1.0)      | 24 (2.9)     | 15 (1.6)    | 17 (1.1)     | 59 (1.7)  |
| Urine albumin/creatinine, mg/g, median (quartiles), n=3220      | 12.0 (5.0; 42.0) | 12.0 (5.0; 49.0) | 10.0 (4.0; 32.0) | 10.0 (5.0; 34.0) | 10.0 (5.0; 36.0) |

Medications, n (%)  

| Any GLD (on diagnosis date)| 174 (60.4) | 493 (59.5) | 592 (64.0) | 900 (60.5) | 2159 (61.2) |
| Any GLD (on DD2 enrollment date) | 282 (97.9) | 716 (86.4) | 837 (90.5) | 1188 (79.9) | 3023 (85.7) |
| Metformin (on diagnosis date) | 166 (57.6) | 480 (57.9) | 562 (60.8) | 867 (58.3) | 2075 (58.8) |
| Metformin (on DD2 enrollment date) | 272 (94.4) | 689 (83.1) | 806 (87.1) | 1151 (77.4) | 2918 (82.7) |
| DPP-4 inhibitors (on diagnosis date) | 3 (1.0)      | 1 (0.1)     | 0 (0.0)    | 5 (0.3)     | 9 (0.3)   |
| DPP-4 inhibitors (on DD2 enrollment date) | 65 (22.6)    | 63 (7.6)    | 101 (10.9) | 89 (6.0)    | 318 (9.0) |
| GLP-1 receptor agonist (on diagnosis date) | 0 (0.0)      | 1 (0.1)     | 1 (0.1)    | 2 (0.1)     | 4 (0.1)   |
| GLP-1 receptor agonist (on DD2 enrollment date) | 50 (17.4)    | 65 (7.8)    | 81 (8.8)   | 15 (1.1)    | 211 (6.0) |
| SGLT-2 inhibitors (on diagnosis date) | 0 (0.0)      | 0 (0.0)     | 0 (0.0)    | 0 (0.0)     | 0 (0.0)   |
| SGLT-2 inhibitors (on DD2 enrollment date) | 6 (2.1)      | 3 (0.4)     | 4 (0.4)    | 1 (0.1)     | 14 (0.4)  |
| Sulfonylureas (on diagnosis date) | 6 (2.1)      | 13 (1.6)    | 25 (2.7)   | 34 (2.3)    | 78 (2.2)  |
| Sulfonylureas (on DD2 enrollment date) | 52 (18.1)    | 48 (5.8)    | 68 (7.4)   | 91 (6.1)    | 259 (7.3) |
| Insulin (on diagnosis date) | 2 (0.7)      | 3 (0.4)     | 9 (1.0)    | 0 (0.0)     | 14 (0.4)  |
| Insulin (on DD2 enrollment date) | 58 (20.1)    | 33 (4.0)    | 73 (7.9)   | 39 (2.6)    | 203 (5.8) |
| Antihypertensive medication (on diagnosis date) | 121 (42.0)  | 597 (72.0)  | 372 (40.2) | 1000 (67.3) | 2090 (59.2) |
| Antihypertensive medication (on DD2 enrollment date) | 195 (67.7)  | 692 (83.4)  | 572 (61.8) | 1124 (75.6) | 2583 (73.2) |
| Lipid-lowering medication (on diagnosis date) | 92 (31.9)    | 447 (53.9)  | 306 (33.1) | 829 (55.8)  | 1674 (47.4) |
| Lipid-lowering medication (on DD2 enrollment date) | 211 (73.3)  | 638 (77.0)  | 611 (66.1) | 1134 (76.3) | 2594 (73.5) |

*Mean (SD) reported for cluster variables. For remaining continuous variables, medians (quartiles) are reported.
†Measured at time of DD2 enrollment, that is, median 1.5 years (quartiles: 0.5; 2.9 years) after diabetes diagnosis date.
‡HbA1c is obtained from linked databases. Measured at a median of 0.8 years (quartiles: 0.1; 2.0 years) after diabetes diagnosis date.
§BMI is obtained from linked databases. Measured at a median of 1.2 years (quartiles: 0.3; 3.4 years) after diabetes diagnosis date.
¶The diabetes diagnosis date was defined as the date of the first indication of diabetes from any available data source including date of first prescription redemption of a glucose-lowering drug (see online supplemental table S2 for details).
BMI, body mass index; CVD, cardiovascular disease; DD2, The Danish Centre for Strategic Research in Type 2 Diabetes Cohort; DPP-4, dipeptidylpeptidase 4; GLD, glucose-lowering drug; GLP-1, glucagon-like peptide 1; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA2-B, homeostatic model assessment 2 beta-cell function; HOMA2-IR, homeostatic model assessment 2 estimates of insulin resistance; LDL, Low-density lipoprotein; MARD, mild age-related diabetes; MOD, mild obesity-related diabetes; SGLT-2, Sodium-glucose cotransporter 2; SIDD, severe insulin-deficient diabetes; SIRD, severe insulin-resistant diabetes; T2D, type 2 diabetes.
Table 2  Patient characteristics: New alternative k-value DD2 Clusters

| Characteristic                                      | New Cluster 1 | New Cluster 2 | New Cluster 3 | Total   |
|----------------------------------------------------|---------------|---------------|---------------|---------|
| Male sex, n (%)                                    | 304 (70.2)    | 612 (54.1)    | 1158 (58.9)   | 2074 (58.8) |
| Diabetes duration on DD2 enrollment date, years, median (quartiles) | 1.6 (0.4; 3.4) | 1.6 (0.5; 2.8) | 1.5 (0.5; 2.8) | 1.5 (0.5; 2.9) |
| Age on diabetes diagnosis date, years, mean (SD)*  | 51.1 (11.2)   | 56.8 (11.2)   | 62.4 (9.8)    | 59.2 (11.2)   |
| Age on DD2 enrollment date, years, median (quartiles) | 53.6 (46.6; 61.5) | 60.1 (61.3; 70.9) | 65.3 (70.9; 70.9) | 62.6 (53.8; 68.9) |
| HOMA2-B, %, mean (SD)†                              | 67.6 (29.8)   | 128.1 (37.4)  | 82.5 (25.2)   | 95.3 (37.9)   |
| HOMA2-IR, mean (SD)††                               | 3.2 (1.4)     | 4.1 (1.4)     | 2.3 (0.8)     | 3.0 (1.4)     |
| HbA1c, mmol/mol, mean (SD)‡                         | 83.5 (18.4)   | 49.0 (7.0)    | 49.6 (5.7)    | 54.2 (15.7)   |
| BMI, kg/m², mean (SD)§                              | 32.2 (5.4)    | 36.1 (5.8)    | 28.1 (3.8)    | 31.1 (6.0)    |
| Waist circumference, cm, median (quartiles), n=2526 | 110 (101; 119) | 116 (108; 125) | 100 (92; 107) | 106 (97; 116) |
| Alcohol, >14/21 units/week (M/F), n (%)             | 21 (4.9)      | 75 (6.6)      | 145 (7.4)     | 241 (6.8)     |
| Days per week with ≥30 min physical activity, n (%) | 77 (17.8)     | 244 (21.6)    | 212 (10.8)    | 533 (15.1)    |
| 1–2                                                | 109 (25.2)    | 270 (23.9%)   | 333 (17.0)    | 712 (20.2)    |
| ≥3                                                  | 247 (57.0)    | 617 (54.6)    | 1420 (72.3)   | 2284 (64.7)   |
| Smoking, n=3225                                     |               |               |               |           |
| Current                                            | 83 (19.2)     | 220 (19.5)    | 320 (16.3)    | 623 (17.7)   |
| Former                                             | 107 (24.7)    | 276 (24.4)    | 478 (24.3)    | 861 (24.4)   |
| Never                                              | 204 (47.1)    | 541 (47.8)    | 996 (50.7)    | 1741 (49.3)  |
| ≥1 relative with diabetes, n (%)                   | 242 (55.9)    | 580 (51.3)    | 1058 (53.8)   | 1880 (53.3)  |
| LDL cholesterol, median (quartiles), n=3412         | 2.6 (1.9; 3.2) | 2.3 (1.8; 2.9) | 2.3 (1.8; 2.9) | 2.3 (1.8; 3.0) |
| HDL cholesterol, median (quartiles), n=2085         | 1.0 (0.9; 1.2) | 1.1 (0.9; 1.3) | 1.3 (1.1; 1.6) | 1.2 (1.0; 1.4) |
| Triglyceride, median (quartiles), n=3343            | 2.2 (1.5; 3.2) | 1.9 (1.4; 2.7) | 1.4 (1.0; 2.0) | 1.6 (1.2; 2.4) |
| Systolic blood pressure, median (quartiles), n=3386  | 134 (125; 142) | 130 (124; 140) | 130 (124; 140) | 130 (124; 140) |
| Diastolic blood pressure, median (quartiles), n=3386 | 83 (60; 90)   | 80 (75; 87)   | 80 (74; 85)   | 80 (75; 86)   |
| Macrovascular complications, n (%)                  |               |               |               |           |
| Any CVD (on diagnosis date)                         | 57 (13.2)     | 249 (22.0)    | 400 (20.4)    | 706 (20.0)   |
| Any CVD (on DD2 enrollment date)                    | 86 (19.9)     | 304 (26.9)    | 489 (24.9)    | 879 (24.9)   |
| Microvascular complications, n (%)                 |               |               |               |           |
| Diabetes+eye disease (on diagnosis date)            | 10 (2.3)      | 50 (4.4)      | 115 (5.9)     | 175 (5.0)    |
| Diabetes+eye disease (on DD2 enrollment date)       | 33 (7.6)      | 78 (6.9)      | 190 (9.7)     | 301 (8.5)    |
| Diabetes+neuropathy (on diagnosis date)             | 26 (6.0)      | 75 (6.6)      | 114 (5.8)     | 215 (6.1)    |

Continued
| Table 2  | Continued |
|----------|-----------|
|          | New Cluster 1 | New Cluster 2 | New Cluster 3 | Total |
| Diabetes-neuropathy (on DD2 enrollment date) | 41 (9.5) | 101 (8.9) | 154 (7.8) | 296 (8.4) |
| Diabetes-renal disease (on diagnosis date) | 3 (0.7) | 15 (1.3) | 9 (0.5) | 27 (0.8) |
| Diabetes-renal disease (on DD2 enrollment date) | 6 (1.4) | 29 (2.6) | 24 (1.2) | 59 (1.7) |
| Urine albumin/creatinine, mg/g, median (quartiles), n=3220 | 12.0 (5.0; 38.0) | 11.0 (5.0; 43.0) | 10.0 (4.0; 33.0) | 10.0 (5.0; 36.0) |

Medications, n (%)

- **Any GLD** (on diagnosis date)†¶ 259 (59.8) 686 (60.7) 1214 (61.8) 2159 (61.2)
- **Any GLD** (on DD2 enrollment date) 426 (98.4) 977 (86.4) 1620 (82.4) 3023 (85.7)
- Metformin (on diagnosis date) 247 (57.0) 666 (58.9) 1162 (59.1) 2075 (58.8)
- **Metformin** (on DD2 enrollment date) 408 (94.2) 947 (83.7) 1563 (79.5) 2918 (82.7)
- **DPP-4 inhibitors** (on diagnosis date) 4 (0.9) 0 (0.0) 5 (0.3) 9 (0.3)
- **DPP-4 inhibitors** (on DD2 enrollment date) 94 (21.7) 81 (7.2) 143 (7.3) 318 (9.0)
- GLP-1 receptor agonist (on diagnosis date) 0 (0.0) 2 (0.2) 2 (0.1) 4 (0.1)
- **GLP-1 receptor agonist** (on DD2 enrollment date) 73 (16.9) 88 (7.8) 49 (2.5) 211 (6.0)
- SGLT-2 inhibitors (on diagnosis date) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
- **SGLT-2 inhibitors** (on DD2 enrollment date) 8 (1.9) 3 (0.3) 3 (0.2) 14 (0.4)
- **Sulfonylureas** (on diagnosis date) 10 (2.3) 19 (1.7) 49 (2.5) 78 (2.2)
- **Sulfonylureas** (on DD2 enrollment date) 78 (18.0) 58 (5.1) 123 (6.3) 259 (7.3)
- Insulin (on diagnosis date) 3 (0.7) 4 (0.4) 7 (0.4) 14 (0.4)
- **Insulin** (on DD2 enrollment date) 78 (18.0) 42 (3.7) 83 (4.2) 203 (5.8)
- Antihypertensive medication (on diagnosis date) 172 (39.7) 757 (66.9) 1161 (59.1) 2090 (59.2)
- **Antihypertensive medication** (on DD2 enrollment date) 286 (66.1) 898 (79.4) 1399 (71.2) 2583 (73.2)
- Lipid-lowering medication (on diagnosis date) 142 (32.8) 558 (49.3) 974 (49.6) 1674 (47.4)
- **Lipid-lowering medication** (on DD2 enrollment date) 317 (73.2) 831 (73.5) 1446 (73.6) 2594 (73.5)

*Mean (SD) reported for cluster variables. For remaining continuous variables, medians (quartiles) are reported.

†Measured at time of DD2 enrollment, that is, median 1.5 years (quartiles: 0.5; 2.9 years) after diabetes diagnosis.
‡HbA1c is obtained from linked databases. Measured at a median of 0.8 years (quartiles: 0.1; 2.0 years) after diabetes diagnosis date.
§BMI is obtained from linked databases. Measured at a median of 1.2 years (quartiles: 0.3; 3.4 years) after diabetes diagnosis.
¶The diabetes diagnosis date was defined as the date of the first indication of diabetes from any available data source including date of first prescription redemption of a glucose-lowering drug (see online supplemental table S2 for details).

BMI, body mass index; CVD, cardiovascular disease; DD2, The Danish Centre for Strategic Research in Type 2 Diabetes Cohort; DPP-4, dipeptidylpeptidase 4; GLD, glucose-lowering drug; GLP-1, glucagon-like peptide 1; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA2-B, homeostatic model assessment 2 beta-cell function; HOMA2-IR, homeostatic model assessment 2 estimates of insulin resistance; LDL, low-density lipoprotein; SGLT-2, Sodium glucose cotransporter 2.
among those with the hyperinsulinemic phenotype (online supplemental table S4).

Additional analyses
In the sensitivity analysis restricted to patients with pretreatment HbA1c measurements (n=739), we observed a distribution of patients and cluster variables similar to that in the main analysis, with the exception that HbA1c was higher in the SIDD group in this analysis and as such was more comparable with the ANDIS cohort. A total of 15 (SIDD: n=2, SIRD: n=1, MOD: n=5, MARD: n=7) individuals had high insulin sensitivity and high beta-cell function (i.e., neither insulinopenic, classical, or hyperinsulinemic type 2 diabetes). In the previous DD2 phenotype study, this was considered to be HOMA2 values in the non-diabetes area, and the individuals were therefore not classified. We did not exclude these 15 individuals in our study; however, they are not shown in figure parts B and C. ANDIS, All New Diabetics in Scania; DD2, Danish Centre for Strategic Research in Type 2 Diabetes; HOMA2, homeostatic model assessment 2; MARD, mild age-related diabetes; MOD, mild obesity-related diabetes; SIDD, severe insulin-deficient diabetes; SIRD, severe insulin-resistant diabetes.

Patient distributions changed moderately when patients were assigned to clusters based on coordinates from the ANDIS cohort (figure 2D). Most notably, 34% of patients assigned to the SIDD cluster and 38% of patients assigned to the SIRD cluster in the de novo cluster analysis were redistributed to the MOD cluster when the ANDIS centroids were used. Similarly, 32% of patients from the de novo MOD cluster were redistributed to the MARD cluster, while almost all (97%) MARD patients were also allocated to the MARD cluster while using ANDIS centroids (boxplots for the main de novo analysis and the cluster assignment based on coordinates are available in online supplemental figures S4 and S9, respectively).

It seemed like cluster assignment was especially sensitive to HbA1c and age, as omitting one of these
variables changed the patient distribution markedly (online supplemental figure S10). Omitting HOMA2-IR, HOMA2-B, or BMI did not cause major changes to the patient distribution.

**DISCUSSION**

Our study yielded two important findings. First, we were able to replicate the four T2D clusters identified in the Swedish ANDIS cohort in the Danish DD2 cohort,\(^2\) by applying a similar data-driven cluster analysis using the same key clinical variables—age, BMI, HbA1c, C-peptide, and plasma glucose—and a priori assuming four T2D clusters. However, the data seemed more compatible with three rather than four clusters. Second, when we compared the identified four (replication of the Swedish clusters) or three (alternative k-value) data-driven clusters with the previously ascertained three Danish HOMA2-based phenotypes, our data showed differences in the classification of patients. HbA1c levels in the SIDD cluster were slightly lower in the Danish DD2 cohort than the Swedish ANDIS cohort,\(^2\) which is likely explained by the inclusion of patients both untreated and treated with glucose-lowering drugs in the DD2 cohort. Consequently, the Danish SIDD cluster accounted for only 8% of the patients (approximately 15% in the Swedish ANDIS cohort). However, in full agreement with the ANDIS results, the DD2 SIDD cluster distinguished patients with clearly higher HbA1c levels, compared with average HbA1c levels in the three other T2D clusters. Apart from HbA1c level in the SIDD cluster, there were strong overlaps between the replicated four T2D clusters with respect to the cluster variables. This may explain the uncertainty with respect to define and differentiate the right and/or clinically relevant number of T2D classes.

It is important to emphasize that the k-means clustering of patients is based on a simple data-driven method rather than a physiologically unique allocation of individuals into T2D classes. Moreover, the ‘true’ number of T2D clusters is not a fully objective assessment but depends on subjective choices, both on the ‘input side’ (ie, choice of cluster variables) and ‘output side’ (ie, determining the number of clusters). While all five clinical variables applied in the Swedish cluster analyses are clinically and physiologically justifiable, other meaningful clusters could have resulted from selecting another set of patient characteristics. In addition, the suggested optimal number of clusters, \(k\), is generally based on simple inspection of graphical plots. Our main method, the average silhouette method, suggested that presence of three clusters in the DD2 cohort was most likely. This was closely followed by two clusters. The likelihood of four or more clusters was clearly lower (online supplemental figure S5A). Using the silhouette method, we therefore conclude that the optimal number of distinct clusters based on the Swedish input variables in our DD2 cohort is closer to three than to four. However, alternative cluster number evaluation methods pointed towards the existence of five or six clusters (online supplemental figure S5B,C), challenging the identification of a definitive number of distinct T2D classes. Moreover, the validity of the clusters for clinical predictions has not yet been established. In their analyses based on the A Diabetes Outcome Progression Trial (ADOPT) and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Dennis et al\(^{17}\) concluded that age at diabetes diagnosis predicted glycemic progression just as well as the T2D clusters. Alternative simple models combining age, sex, baseline HbA1c, and BMI also predicted response to glycemic treatment better than the clusters per se.\(^{17}\)

Other studies also have striven to identify novel T2D clusters in Asian,\(^{11-15,18}\) Latin American,\(^{19-21}\) and Caucasian\(^{14-16,19-21}\) diabetes patients using k-means cluster analysis. Some have used a fixed k-value of four in order to replicate the original Swedish clusters,\(^{17,18}\) whereas others\(^{14-16,19-21}\) have applied an analytical approach allowing for a wider range of clusters and/or included cluster variables other than those originally used. Our DD2 MOD cluster seemed less well defined, as patients from this cluster reallocated to all three new alternative k-value DD2 clusters. Consistent with this observation, Safai et al\(^{20}\) did not identify a MOD-like cluster in their de novo cluster analysis (which also included diabetes duration and GADA titer as cluster variables) and two of their four
clusters were very similar except for diabetes duration. They possibly may have had ended up with three clusters if they had not added diabetes duration as cluster variable. Similarly, other studies did not find their MOD-like clusters to have the highest BMI\textsuperscript{15,25} or did not support $k=4$ as the most optimal number of T2D clusters.\textsuperscript{16}

Using a pathophysiological insulin secretion and action based approach (HOMA\textsuperscript{2} estimates) as the core fundament for defining T2D classes is a feature common to both the Swedish cluster-based and the Danish phenotype classification proposals. For this reason, we considered it likely that our new three-cluster DD2 grouping would classify patients in a manner similar to the three phenotypes. However, this was not the case, as most patients in New Cluster 1 (insulin deficiency) and New Cluster 3 (high age) were allocated to the classical phenotype. New Cluster 2 (hyperinsulinemia) appeared to be the most distinct across classification approaches, with the majority of patients reallocated to the hyperinsulinemic phenotype.

The pathophysiology of T2D involves multiple organs with or without influence on insulin secretion or sensitivity, and HOMA\textsuperscript{2} estimates are at best surrogate measures of the actual (but not completely understood) defects of pancreatic insulin secretion and/or insulin sensitivity. First, HOMA\textsuperscript{2}-B and HOMA\textsuperscript{2}-IR are calculated using the same unstimulated fasting plasma glucose and serum C-peptide levels and therefore are correlated and interrelated. Second, HOMA\textsuperscript{2} estimates in patients with diabetes may be flawed by use of glucose-lowering medications.\textsuperscript{23} Slieker \textit{et al}\textsuperscript{21} included HDL cholesterol and C-peptide measurements instead of HOMA\textsuperscript{2} for subgrouping analyses in patients with T2D. They identified five instead of four T2D clusters, of which two mimicked the original MARD cluster but with different HDL levels. Whether the most correct and clinical meaningful T2D classification can be defined using pathophysiological factors or rather etiological factors, biomarkers unrelated to the underlying cause of the disease, and/or disease trajectories needs further investigation.

Regardless, using the proposed insulin secretion/action based approaches, the SIRD cluster and the hyperinsulinemic phenotype appear to be among the most distinct classes. These T2D classes, characterized by high beta-cell function, are reported to have the highest prevalence of diabetic kidney disease.\textsuperscript{1,2,14} They also are associated with abdominal obesity\textsuperscript{3} and increased liver fat content\textsuperscript{24} and furthermore represent the T2D classes most likely to be associated with elevated cardiovascular risk, which is further supported by our results.\textsuperscript{2,3} Interestingly, the Swedish SIRD cluster stood out from the others, with lower heritability and a lower diabetes genetic risk score.\textsuperscript{2,25} This is supported by our findings. The SIRD cluster therefore may have a different etiological background than the other T2D classes. Further studies on the long-term prognostic utility of T2D classifications are needed.

Optimally, validation of the clusters proposed by Ahlqvist \textit{et al} should be performed in treatment-naive new-onset T2D patients. This has not been possible in most studies to date.\textsuperscript{14,15,19-22,24} Likewise, HbA1c and HOMA\textsuperscript{2} measurements were not available for all DD2 patients prior to initiation of glucose-lowering treatment. However, we obtained virtually identical results in the sensitivity analysis restricted to those with available pretreatment HbA1c measurements.

The DD2 cohort aims to enroll T2D patients. Consequently, the proportion of GADA-positive patients is small compared with the original Swedish cohort. However, the SAID cluster was defined solely on GADA positivity in the original Swedish study, that is, that cluster was identified before running the $k$-means cluster analysis. Thus, the low proportion of GADA-positive DD2 patients did not hamper our T2D cluster analysis.

More than one-third of the source population was excluded due to missing data on cluster variables. However, patient characteristics were comparable across included and excluded individuals (online supplemental table S5). Also, the DD2 cohort only included ~5% of Danish individuals diagnosed with T2D during the study period. However, characteristics of the DD2 patients are similar to those of average newly diagnosed Danish T2D patients.\textsuperscript{26}

In conclusion, we found evidence that different HOMA\textsuperscript{2}-based approaches do not classify T2D patients consistently. There may be a need for additional biomarkers covering T2D etiology, pathophysiology, and outcomes in order to define robust and clinically relevant T2D classes.

\section*{Author affiliations}
\begin{itemize}
  \item Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark
  \item Genomics, Diabetes and Endocrinology Unit, Department of Clinical Sciences, Lund University Diabetes Center, Malmö, Sweden
  \item The Danish Centre for Strategic Research in Type 2 Diabetes (DD2), Odense University Hospital, Odense, Denmark
  \item Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark
  \item Department of Clinical Research, University of Southern Denmark, Odense, Denmark
  \item Department of Internal Medicine and Steno Diabetes Center Zealand, Holbæk Hospital, Holbæk, Denmark
  \item Department of Regional Health Research, University of Southern Denmark, Odense, Denmark
  \item Department of Nutrition, Food Science and Physiology, University of Navarra, Pamplona, Spain
  \item Epigenetic and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Center, Scania University Hospital, Malmö, Sweden
  \item Department of Endocrinology IC, Bispebjerg University Hospital, Copenhagen, Denmark
  \item Copenhagen Center for Translational Research, Bispebjerg University Hospital, Copenhagen, Denmark
  \item Department of Clinical Biochemistry, University of Southern Denmark, Vejle, Denmark
  \item Steno Diabetes Center Aalborg, Aalborg University Hospital, Aalborg, Denmark
  \item Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
  \item The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  \item Steno Diabetes Center Copenhagen, Gentofte Hospital, Gentofte, Denmark
\end{itemize}

\section*{Acknowledgements}
We are grateful to all Danish Centre for Strategic Research in Type 2 Diabetes (DD2) participants as well as to the staff in outpatient hospital
clinics, hospital clinical laboratories, and general practitioners participating in the enrollment. We would like to sincerely thank the D22 staff.

Contributors RWT, AV, EA, and CL conceived the study idea. DHC, SKN, EA, CL, SG-C, RWT, and AV designed the study. JSN is the principal manager of the D22. SKN performed the statistical analysis. DHC, SKN, RWT, and AV prepared the first draft. All authors contributed to the interpretation of data, to the drafting of the manuscript as well as critically revised the manuscript draft. All authors gave final approval of the version to be published. SKN, DHC, RWT, and AV are the guarantors of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. RWT and AV are joint last authors.

Funding The D22 study was supported by the Danish Agency for Science (grant numbers 09-067009 and 09-075724), The Danish Health and Medicines Authority, The Danish Diabetes Association, Region Southern Denmark, and the Novo Nordisk Foundation (grant numbers NNF17SA0030962-2 and NNF2000683292). The D22 biobank was supported by an unrestricted donation from Novo Nordisk A/S. Project partners are listed on the website www.d22.nu.

Disclaimer The sponsors had no role in study design, in data collection, analysis, and interpretation, or in drafting, revising or approving the manuscript for submission.

Competing interests The Department of Clinical Epidemiology, Aarhus University Hospital, receives funding for other studies from companies in the form of institutional research grants to (and administered by) Aarhus University. None of these studies has any relation to the present study. JCS, KH, MHO, PN, NJ, CB, and AV are all affiliated with Danish Steno Diabetes Centers. The Steno Diabetes centers are funded by the Novo Nordisk Foundation. EA was funded by grants from the Swedish Research Council (2017-02688, 2020-02191) and the Novo Nordisk foundation (NNF18CC0034408).

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by Denmark’s Regional Ethical Committee on Health Research (Record number S-20100082) and by the Danish Data Protection Agency [record number 2008-58-0035 and 2016-05-00001/2514]. All D22 participants volunteered to participate in the D22 project and gave written informed consent.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. More information about the D22 cohort can be found at the D22 website: www.d22.nu. The D22 project has a Steering Group that strongly encourages national and international collaboration. Interested researchers can contact Professor Kurt Hjellmand at Kurt.Hjellmand@syd.dk. According to Danish data protection legislation, linked individual-level register data analyzed in the study cannot be shared or made publicly available. Register data are stored at the Danish Health Data Authority and can be made available for research on reasonable request and with permission from the Danish Data Protection Agency.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Diana Hedevang Christensen http://orcid.org/0000-0002-2693-5651

REFERENCES
1 WHO. World Health Organization. Vol. 2021, 2021.